Robert W. Baird initiated coverage on Alumis with a new price target
$ALMS
Biotechnology: Pharmaceutical Preparations
Health Care
Robert W. Baird initiated coverage of Alumis with a rating of Outperform and set a new price target of $25.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2024 | $25.00 | Outperform | Robert W. Baird |
| 10/17/2024 | $30.00 | Buy | H.C. Wainwright |
| 7/23/2024 | Overweight | Cantor Fitzgerald | |
| 7/23/2024 | $29.00 | Outperform | Leerink Partners |
| 7/23/2024 | $32.00 | Buy | Guggenheim |
| 7/23/2024 | $36.00 | Overweight | Morgan Stanley |
Robert W. Baird initiated coverage of Alumis with a rating of Outperform and set a new price target of $25.00
H.C. Wainwright initiated coverage of Alumis with a rating of Buy and set a new price target of $30.00
Cantor Fitzgerald initiated coverage of Alumis with a rating of Overweight
10-Q - ALUMIS INC. (0001847367) (Filer)
8-K - ALUMIS INC. (0001847367) (Filer)
10-Q - ALUMIS INC. (0001847367) (Filer)
4/A - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced the company will give two data presentations at ACR Convergence 2024, the annual meeting of the American College of Rheumatology (ACR), being held November 14–19, 2024, in Washington, D.C. Data to be presented at ACR show that treatment with ESK-001, a highly selective allosteric oral tyrosine kinase 2 (TYK2) inhibitor, suppresses both a novel disease biomarker as well as Type 1 inte
– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, including global Phase 3 ONWARD clinical trials for ESK-001 in moderate-to-severe plaque psoriasis, Phase 2b clinical trial for ESK-001 in systemic lupus erythematosus (SLE) and Phase 1 clinical study for A-005 being developed for neuroinflammatory and neurodegenerative diseases – SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcome
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 2:00 pm ET in Boston, MA. A live webcast will be available on the Alumis website in the "Investors" section under the "Events" page. A replay of the conference webcast will be archived on t
Guggenheim Partners initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. The investment thesis centers around a positive view of its lead asset ESK-001, a next-gen TYK2 inhibitor currently in development for plaque psoriasis and systemic lupus erythematosus (SLE). The company’s management expects to initiate a Phase 3 trial for plaque psoriasis in the second half of 2024, and data from the SLE study are expected in 2026. The analyst writes that favorable safety (with no risk of JAK class black box warning) and potential BIC efficacy make ESK-001 a potentially competitive alternative to ava
CORRECTION: Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Alumis (NASDAQ:ALMS) with a Overweight rating.
Guggenheim analyst Yatin Suneja initiates coverage on Alumis (NASDAQ:ALMS) with a Buy rating and announces Price Target of $32.
4/A - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
SC 13D - ALUMIS INC. (0001847367) (Subject)
SC 13G - ALUMIS INC. (0001847367) (Subject)
SC 13D - ALUMIS INC. (0001847367) (Subject)